Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2301 - 2325 of 14929 in total
Etofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued .
Approved
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …
Approved
Experimental
Matched Categories: … Blood and Blood Forming Organs …
Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. Bulevirtide, also known as Hepcludex, is a...
Approved
Investigational
Matched Description: … of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. ... Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development ... first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Peanut oil is derived from Arachis hypogaea which can be found in South America, Mexico, and Centro America. The kernels are consumed roasted but a large percentage is used for the production of vegetable oil. The peanut oil represents about 45-52% of the kernel content and it is mainly formed...
Approved
Matched Description: … Peanut oil is derived from _Arachis hypogaea_ which can be found in South America, Mexico, and Centro ... The peanut oil represents about 45-52% of the kernel content and it is mainly formed from monounsaturated …
Matched Categories: … Basic Ointments and Protectants …
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … indirectly, in the growth and proliferation of tumors in which it is overexpressed and/or mutated. ... ] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma. ... [A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. ... rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and ... It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011 …
Matched Categories: … indacaterol and mometasone ... indacaterol and glycopyrronium bromide ... indacaterol, glycopyrronium bromide and mometasone …
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … DM4 leads to cell-cycle arrest and apoptosis and is also able to diffuse into neighboring cells and induce ... [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and ... the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Approved
Matched Description: … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties.[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity...
Approved
Investigational
Matched Description: … adolescents aged 16 years and older. ... Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory ... L45424] The use of omaveloxolone for the treatment of conditions involving mitochondrial dysfunction and
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Karaya gum allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Equipment and Supplies ... Alimentary Tract and Metabolism …
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
Approved
Investigational
Matched Description: … Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and
Matched Categories: … Nitrates and Nitrites ... Indicators and Reagents …
Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular system, sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst...
Approved
Investigational
Matched Description: … soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and ... thereby helps to prevent the myocardial and vascular dysfunction associated with decreased sGC activity ... messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins …
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases...
Approved
Investigational
Matched Description: … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads ... to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. ... The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to …
Matched Categories: … alfuzosin and finasteride ... Genito Urinary System and Sex Hormones …
Dolichovespula arenaria venom protein is an extract of Dolichovespula arenaria venom. Dolichovespula arenaria venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Vespula vulgaris venom protein is an extract of Vespula vulgaris venom. Vespula vulgaris venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a...
Approved
Investigational
Matched Description: … [A235174] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor.[A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is...
Approved
Investigational
Matched Description: … Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. ... to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and ... [A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such …
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Approved
Matched Description: … used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and ... [A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. ... was approved in July 2022 -,[L42495] adalimumab-bwwd - which was approved in August 2022 -,[L42935] and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the...
Approved
Illicit
Investigational
Withdrawn
Matched Description: … increases the risk of heart attack and stroke in patients with a history of heart disease. ... Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide ... In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug …
Matched Categories: … Alimentary Tract and Metabolism ... Serotonin and Noradrenaline Reuptake Inhibitors ... Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic …
Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant . It is listed as a prescription drug in New Zealand legislation . Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation .
Approved
Matched Categories: … Cough and Cold Preparations …
Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG). Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange. It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia...
Approved
Investigational
Matched Description: … by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November 2020. ... Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. ... [A260177] It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is...
Approved
Matched Description: … Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic ... It is also found in plants and is used pharmacologically as a sympathomimetic. ... Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse …
Matched Categories: … Epinephrine and similars ... Adrenergic and Dopaminergic Agents ... Alpha-and Beta-adrenergic Agonists …
Displaying drugs 2301 - 2325 of 14929 in total